Treatment protocol for B-cell non-Hodgkin lymphoma in children and adolescents
Tests different chemotherapy combinations in children and teens with B-cell lymphoma, based on risk.
Key facts
- Who runs it
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Where
- Moscow, RussiaSee the site
- Trial code
- Registry title
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 300 people, planned
- Started
- 25 May 2022
- Expected to end
- 16 May 2027
- Type of study
- Interventional, 4 groups
- Treatments tested
- Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
- Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
- Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
- Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
- Record updated
- 26 August 2022
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children and adolescents with newly diagnosed mature B-cell non-Hodgkin lymphoma, such as Burkitt lymphoma, diffuse large B-cell lymphoma, primary mediastinal lymphoma or primary CNS lymphoma.
- Age
- 0 to 18 years at diagnosis
- Sex
- All
- Disease stage
- Burkitt lymphoma, diffuse large B-cell lymphoma, primary mediastinal lymphoma, primary CNS lymphoma or B-cell (Burkitt) acute leukaemia
- Earlier treatment
- Previous cancer is not allowed.
Main reasons for not taking part
- Previous cancer
- Prior organ transplant
- HIV infection or AIDS, or severe immunodeficiency
- Allergy to rituximab or to ingredients of the other trial drugs
- No informed consent from parents or guardians
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Age at diagnosis 0 to 18 years
- The diagnosis of Burkitt's lymphoma, Diffuse large B-cell lymphom, primary mediastinal lymphoma, primary CNS lymphoma, B-cell (Burkitt) AL
- Informed consent of the patient parents (guardians) to be treated
Who cannot take part
- previous malignancy, prior organ transplant, HIV infection or AIDS or severe immunodeficiency
- hypersensitivity to rituximab or to ingredients of other IMPs
- no informed consent of the patient parents (guardians) to be treated
Where in Russia
- Dmitry Rogachev National Medical Research Center Of Pediatric Hematology, Oncology and ImmunologyMoscow, RussiaContact: Yulia AbugovaTaking people
About the trial
What the trial wants to find out
The aim of the trial is to evaluate the molecular characteristics and MDD/MRD of B-NHL in pediatric patients in order to identify on the one hand the very high risk group and to prescribe them more intensive treatment on the other hand to identify those patients who don't need very aggressive therapy. One more study question is to evaluate the role of PET/CT in assessment of the completeness of remission.
Read full original descriptionShow less
The following primary study questions are going to be analyzed:
* the effectiveness (event-free survival) in pediatric patients with very limited mature B-NHL (R1 - stage I and II R) of substituting anthracyclines and vincristine by the rituximab without compromising survival rates. * the effectiveness (event-free survival) in pediatric patients with limited mature B-NHL (R2 - stage I and II NR) of substituting anthracyclines by the rituximab without compromising survival rates. * the effectiveness (event-free survival) in pediatric patients with advanced VHR mature B-NHL (R4 - stages with unfavourable genetics of substituting standard chemotherapy by "second-line" block VICI in order to improve results
Secondary study questions will address
* additional parameters for immune reconstitution, lymphocyte subpopulations, immunoglobulin levels, vaccination titers and infection rates * kinetics of immune reconstitution after treatment
The 4 groups in the trial
- R1: stage I and IITreatment being tested
R1: resection status: complete, stage I and II
Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate
- R2: incomplete, stage I and IITreatment being tested
R2: resection status: incomplete, stage I and II
Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine
- R3: incomplete, stage III and LDH < 2 x ULNTreatment being tested
R3: resection status: incomplete, stage III and LDH \< 2 x ULN
Treatment: Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine
- R4: stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +Treatment being tested
R4: resection status: incomplete, stage III and LDH ≥ 2 x ULN, stage IV/B-AL and CNS negative; CNS +
Treatment: Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)
- Plain-language title
- Treatment protocol for B-cell non-Hodgkin lymphoma in children and adolescentsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 26 August 2022